Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGOB131 is a patented and standardized seed extract derived from the West African plant *Irvingia gabonensis*, commonly known as African mango. It is primarily used as a dietary supplement for weight management and metabolic wellness. Clinical studies have shown that IGOB131 can significantly reduce body weight, waist circumference, and body fat in overweight or obese individuals. The mechanism of action involves modulation of key metabolic pathways related to adipogenesis—specifically impacting PPAR gamma activity, increasing adiponectin levels (which enhances energy balance and reduces fat cell size), decreasing leptin (regulating appetite and satiety), lowering C-reactive protein (a marker of inflammation), improving cholesterol profiles (total cholesterol and LDL cholesterol), reducing blood glucose levels, and inhibiting the enzyme glycerol-3-phosphate dehydrogenase involved in fat storage[2][3][4][7]. The ingredient is generally well-tolerated with mild side effects such as flatulence or headache reported at rates similar to placebo[1][2]. It has been granted U.S. FDA GRAS status.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on irvingia gabonensis seed extract.